Cash Flow Divergence and a Late Auditor Resignation

The headline growth is not supported by cash. CFO/PAT fell to about 0.32× from about 1.1×, a major deterioration. A rough working-capital bridge explains part of the gap: with revenue of INR 18.4 billion, DSO of 92 days implies receivables of about INR 4.6 billion, versus about INR 2.4 billion at 48 days - an increase of roughly INR 2.2 billion. Inventory days rising from 60 to 88 implies additional inventory of roughly INR 1.4 billion if cost of goods sold is about INR 14 billion. Those two movements absorb cash and can easily explain why CFO fell even as PAT rose.

The analyst should ask whether the receivables are genuine trade receivables or include channel financing, related-party balances, or sales with extended credit terms. Revenue recognition should be tested: were sales pulled forward at quarter-end, were discounts or rebates accrued, and are receivables ageing? Inventory growth should be split between new stores and slow-moving stock. Capitalised product development of INR 1.2 billion also flatters EBITDA and PAT if the spending would otherwise be expensed; the analyst should check the capitalisation policy, amortisation period, and whether the projects have future economic benefit.

A useful test is whether CFO would still cover PAT after adjusting for the working-capital build and capitalised costs. On the facts, it would not.

Each item matters for a different reason:

• Auditor resignation in February is a serious red flag. Resignations close to year-end can signal disagreements over accounting, scope limitations, or internal controls. The analyst should seek the resignation letter and any exchange disclosure, and ask the new auditor about the transition.
• New auditor appointed in March may have limited time to complete a rigorous audit. The analyst should check whether the audit opinion is clean, whether there were any qualifications, and whether the new auditor had access to prior-year workpapers.
• Related-party purchases at 18% of raw-material cost raise transfer-pricing and earnings-quality questions. Are the prices at arm's length? Is the related party a shell? Does the promoter benefit at the expense of minority shareholders?
• Capitalisation of product development can shift expenses from the P&L to the balance sheet, inflating near-term margins and return ratios. The analyst should compare capitalised amounts with the amortisation charge and with peers' policies.
• Promoter pledge of 35% creates forced-selling risk if the share price falls. It also signals that the promoter may have liquidity needs, which can increase related-party transaction risk.

These are not isolated items. Together they suggest that reported earnings may be less durable and that governance risk is higher than the multiple implies.

Diligence should include:

1. Cash-flow reconciliation for the last three years, including a bridge from PAT to CFO and a breakdown of working capital.
2. Receivables ageing and concentration, with a check for related-party or overdue balances and any channel financing.
3. Inventory ageing by category and store, and a comparison of new-store inventory with mature-store inventory.
4. Capitalisation policy and project-wise details of product development, including impairment history.
5. Related-party transactions: names, relationships, pricing, and whether the counterparties are audited.
6. Auditor change: resignation letter, exchange filings, management representation letter, and the new auditor's opinion.
7. Promoter pledge: lender details, trigger levels, and any share sale.

A Buy rating based on 40× forward earnings is not supported while these issues are unresolved. The appropriate action is to suspend or withdraw the target price, move to a Hold or Under Review stance, and disclose the diligence gaps. If the receivables and capitalisation are not substantiated, the earnings base should be reduced and the rating could be Sell. The analyst should not wait for the new auditor's annual report if exchange disclosures already raise doubts.